HORMESIS PERVASIVENESS AND ITS POTENTIAL IMPLICATIONS FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT

被引:11
作者
Maynard, Kenneth I. [1 ]
机构
[1] Sanofi US Inc, Bridgewater, NJ 08807 USA
来源
DOSE-RESPONSE | 2011年 / 9卷 / 03期
关键词
dose response; hormesis; drug discovery; drug development; research and development; pharmaceutical industry; FOCAL CEREBRAL-ISCHEMIA; ARTERY OCCLUSION; INFARCT VOLUME; DOSE-RESPONSE; DELAYED TREATMENT; WISTAR RATS; INHIBITOR; PROTECTS; BW619C89; MODEL;
D O I
10.2203/dose-response.11-026.Maynard
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This mini-review illustrates that hormesis is not only confined to the areas of biochemistry, radiation biology and toxicology, where it is traditionally known, but illustrates, by citing published scientific literature, that it is found across a wide range of biomedical science and clinical medicine such as neuroscience, cardiology and oncology. The use of techniques and technology, including high through-put screening, micro-dosing or phase 0 studies, pharmacometrics and adaptive trial design in the clinic, are proposed to illustrate how acknowledging the potential impact of hormesis throughout different stages of drug discovery and development, including hurdles related to efficacy and safety, could help the pharmaceutical industry address some of its major and frequently mentioned challenges.
引用
收藏
页码:377 / 386
页数:10
相关论文
共 28 条
[1]   The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells [J].
Andoh, T ;
Chock, PB ;
Chiueh, CC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (12) :9655-9660
[2]   Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats [J].
Ayoub, IA ;
Lee, EJ ;
Ogilvy, CS ;
Beal, MF ;
Maynard, KI .
NEUROSCIENCE LETTERS, 1999, 259 (01) :21-24
[3]   Hormesis and medicine [J].
Calabrese, Edward J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (05) :594-617
[4]   Dose-response features of neuroprotective agents: An integrative summary [J].
Calabrese, Edward J. .
CRITICAL REVIEWS IN TOXICOLOGY, 2008, 38 (04) :253-348
[5]   Neuroscience and hormesis: Overview and general findings [J].
Calabrese, Edward J. .
CRITICAL REVIEWS IN TOXICOLOGY, 2008, 38 (04) :249-252
[6]   Neuroprotective effects of progesterone after transient middle cerebral artery occlusion in rat [J].
Chen, JL ;
Chopp, M ;
Li, Y .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 171 (01) :24-30
[7]   Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999 [J].
Cross, J ;
Lee, H ;
Westelinck, A ;
Nelson, J ;
Grudzinskas, C ;
Peck, C .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2002, 11 (06) :439-446
[8]   Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2):: Observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth [J].
Donate, Fernando ;
Parry, Graham C. ;
Shaked, Yuval ;
Hensley, Harvey ;
Guan, Xiaojun ;
Beck, Ivy ;
Tel-Tsur, Ziva ;
Plunkett, Marian L. ;
Manuia, Mari ;
Shaw, David E. ;
Kerbel, Robert S. ;
Mazar, Andrew P. .
CLINICAL CANCER RESEARCH, 2008, 14 (07) :2137-2144
[9]   Dextrorphan reduces infarct volume, vascular injury, and brain edema after ischemic brain injury [J].
Du, C ;
Hu, R ;
Hsu, CY ;
Choi, DW .
JOURNAL OF NEUROTRAUMA, 1996, 13 (04) :215-222
[10]  
Dudekula Noor, 2005, Dose-Response, V3, P414, DOI 10.2203/dose-response.003.03.009